Oricula Therapeutics, LLC

Seattle, WA 98112

SBIR Award Summary

Total Number of Awards 3
Total Value of Awards $2.23MM
First Award Date 04/01/14
Most Recent Award Date 01/01/17

Key Personnel

Last Name Name Awards Contact
GLESER MALCOLM GLESER 3
JOHNSON GRAHAM JOHNSON 3

3 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 01/01/17 - 12/31/17

? DESCRIPTION (provided by applicant): Aminoglycoside antibiotics (AGs) are important for the treatment of a variety of serious infectious diseases including septicemia, complicated intra-abdominal infections, complicated urinary tract infections, and nosocomial respiratory tract infections. AGs are the mainstay of treating Pseudomonas infect...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 01/11/16 - 12/31/16

? DESCRIPTION (provided by applicant): Aminoglycoside antibiotics (AGs) are important for the treatment of a variety of serious infectious diseases including septicemia, complicated intra-abdominal infections, complicated urinary tract infections, and nosocomial respiratory tract infections. AGs are the mainstay of treating Pseudomonas infect...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-234
Budget: 04/01/14 - 09/30/14

DESCRIPTION (provided by applicant): Aminoglycoside antibiotics (AGs) are important for the treatment of a variety of serious infectious diseases including septicemia, complicated intra-abdominal infections, complicated urinary tract infections, and nosocomial respiratory tract infections. AGs are the mainstay of treating Pseudomonas infection i...